UNASSIGNED：进行了系统评价和荟萃分析，以更好地了解粒子束疗法对鼻咽癌（NPC）治疗的益处。研究了接受质子或碳离子束治疗的原发性和复发性NPC患者的生存结果和毒性。
未经授权：PubMed，Scopus,和Embase在2007年1月1日至2021年11月3日之间进行了搜索。纳入和排除标准包括原发性或复发性NPC患者的研究，样本量≥10名患者，和质子或碳离子束疗法作为干预措施。纳入了26项符合条件的研究，共1502名患者。我们使用随机效应荟萃分析来检查粒子束治疗对原发性NPC患者的影响，并定性地描述了复发患者的结果。主要结果是总生存期（OS），次要结局包括无进展生存期（PFS），局部控制（LC）和毒性。
UNASSIGNED：1年的池化操作系统，接受粒子束治疗的原发性NPC患者的2年，3年和5年为96％（95％置信区间（CI）=92％-98％），93%（95%CI=83%-97%），90%(95%CI=73%-97%)和73%(95%CI=52%-87%)。合并的1年和2年PFS，这些患者的LC高于90%。对于局部复发的NPC患者，1年OS率从65%到92%不等，而1年LC率从80%到88%不等。质子和碳离子束治疗在原发性和复发性患者中通常是安全的，≥G3的晚期毒性率为20%或更低。据报道，复发患者的死亡率约为5％。
UNASSIGNED：这项系统评价和荟萃分析证明，粒子束疗法在治疗NPC方面具有巨大潜力，产生优异的生存结果，低毒性。然而,需要进一步的研究来评估这种新型放射治疗的长期结局和成本效益.
UNASSIGNED: A systematic review and meta-analysis were performed to better understand the benefits of particle beam therapy for nasopharyngeal cancer (NPC) treatment. The survival outcomes and toxicity of primary and recurrent NPC patients treated with proton or carbon ion beam therapy were investigated.
UNASSIGNED: PubMed, Scopus, and Embase were searched between 1 January 2007 to 3 November 2021. The inclusion and exclusion criteria included studies with either primary or recurrent NPC patients, sample size of ≥10 patients, and proton or carbon ion beam therapy as interventions. Twenty-six eligible studies with a total of 1502 patients were included. We used a random-effect meta-analysis to examine the impact of particle beam therapy on primary NPC patients and qualitatively described the results among recurrent patients. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), local control (LC) and toxicity.
UNASSIGNED: The pooled OS at 1-year, 2-year and 3-year and 5-year for primary NPC patients who received particle beam therapy were 96 % (95 % confidence interval (CI) = 92 %-98 %), 93 % (95 % CI = 83 %-97 %), 90 % (95 % CI = 73 %-97 %) and 73 % (95 % CI = 52 %-87 %) respectively. The pooled 1-year and 2-year PFS, and LC for these patients were above 90 %. For locally recurrent NPC patients, the 1-year OS rate ranged from 65 % to 92 %, while the 1-year LC rate ranged from 80 % to 88 %. Both proton and carbon ion beam therapy were generally safe among primary and recurrent patients, with ≥G3 late toxicity rates of 20 % or less. Approximately a 5 % mortality rate was reported among recurrent patients.
UNASSIGNED: This systematic review and meta-analysis demonstrated particle beam therapy has great potential in treating NPC, yielding excellent survival outcomes with low toxicity. However, further investigations are needed to assess the long-term outcomes and cost-effectiveness of this newer form of radiotherapy.
PDF(Pubmed)